GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

Status
UnknownResults none
Why it is watched
non-weight indication: endocrine, other_emerging
Who it enrolls
age 18 Years to 65 Years; female; excludes diabetes; BMI ≥27 required; conditions: Polycystic Ovary Syndrome; Obesity; Infertility, Female
Interventions
Liraglutide + Metformin; Metformin
Conditions
Polycystic Ovary Syndrome; Obesity; Infertility, Female
Phase and size
Phase 3 · 188 participants
Dates
Start 2023-11-01
Primary completion 2025-12-31
Sponsor
Mỹ Đức Hospital (Other)
Last checked
Sep 13, 2026
01Endpoints

What the trial will measure

  • Absolute Body Weight (BW)12 weeks of treatment
  • Change in Percent Body Weight12 weeks of treatment
02Eligibility

Who can take part

Inclusion Criteria: * Female gender * 18-65 years of age * Diagnosis of polycystic ovary syndrome according to the revised Rotterdam criteria (2003) * BMI ≥ 27 kg/m2 * Infertility * Agree to participate in the study Exclusion Criteria: * Type 1 or type 2 diabetes. * History of acute or chronic pancreatitis. * Family or individual history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 * Known hypersensitivity or contraindication to the use of GLP-1 receptor agonists. * Used of hormonal drugs, drugs causing clinically significant weight changes and drugs affecting glucose tolerance for at least 8 weeks. * Used a anti-androgen drugs for at least 4 weeks. * History of malignancy requiring chemotherapy. * History of taking antidiabetic drugs other than gestational diabetes or weight-loss drugs discontinued for at least 4 weeks. * History of gastrectomy or device-based intervention to manage obesity * Eating disorders (anorexia or bulimia) or digestive disorders. * Substance abuse (Tobacco or alcohol) * History of major depression or other serious mental disorder. * Inability or refusal to adhere treatment regimens.
03Change log

Registry changes

No changes recorded since the trial was added.